American Oriental Bioengineering Inc. Options to Trade on Chicago Board Options Exchange (CBOE).

HONG KONG -- American Oriental Bioengineering Inc. (AMEX: AOB), an emerging Chinese company that produces and distributes a broad range of pharmaceutical and nutraceutical products, announced today that on Thursday, Dec. 1, 2005, options on the company's common stock began trading on the Chicago Board Options Exchange ("CBOE"). The CBOE is the world's largest options marketplace.

American Oriental Bioengineering options trade on the January expiration cycle with exercise limits set at 25,000 contracts on each side. The Designated Primary Market Maker for AOB is Susquehanna Investment Group.

In the last six months, AOBO has taken several steps to improve the visibility of the company's stock. On July 18, 2005, the company's common stock began trading on the American Stock Exchange. On Oct. 26, 2005, options on the company's common stock started trading on Pacific Exchange and most recently on Nov. 11, 2005, the company's common stock was approved for dual listing on the Archipelago Exchange ("ArcaEx"), a facility of the Pacific Exchange, and began trading on ArcaEx on Nov. 11, 2005.

"We are pleased to have our options traded on the largest options marketplace, the Chicago Board Options Exchange, and we believe this is another important event as we continue to improve the visibility and liquidity of our stock," commented Tony Liu, chairman and CEO of American Oriental Bioengineering.

About American Oriental Bioengineering Inc.

American Oriental Bioengineering Inc. (AOBO) uses proprietary processes for producing soybean protein peptide more efficiently than traditional extracting techniques. These techniques are used to manufacture and formulate supplemental and medicinal products. Soybean peptides are used widely in general food, health food products and medicines, among other applications. AOB also produces Cease-Enuresis Soft Gel, the only China state FDA-approved first-grade, plant-based prescription medicine that is specially formulated to help alleviate bed-wetting and incontinence. The company is a leading producer of products in both the nutriceuticals and pharmaceuticals areas in China. For more information, visit http://www.bioaobo.com.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.